Glycosylated Hemoglobin, Cardiovascular, and Renal Outcomes in a Pharmacist-Managed Clinic

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 771-775

  Cioffi, Seth T ^a   Caron, Michael F ^b,c   Kalus, James S ^d   Hill, Patricia ^a   Buckley, Thomas E ^e  

^a Vet Aff Connecticut Hlthcare S   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e PFIZER INC   (United States)

Author keywords

Diabetes mellitus; Glycosylated hemoglobin

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ALBUMINURIA; AMBULATORY CARE FACILITIES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; MALE; PATIENT EDUCATION; PHARMACEUTICAL SERVICES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1942503169     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D359     Document Type: Article

References (18)

1. National Diabetes Information Clearinghouse. www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm#7 (accessed 2003 Jun 6).
2. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-50. Erratum 2003;26:972.
3. Saaddine JB, Engelgau MM, Beckless GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565-74.
4. Willey ML, Chagan L, Sisca TS, Chapple KJ, Callahan AK, Kitenko LE, et al. A pharmacist-managed anticoagulation clinic: six-year assessment of patient outcomes. Am J Health Syst Pharm 2003;60:1033-7.
5. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20:1375-83.
6. Department of Veterans Affairs Veterans Health Administration Office of Quality and Performance. Clinical practice guidelines. www.oqp.med.va.gov/cpg/cpg.htm (accessed 2003 Jul 16).
7. 1c in high-risk patients with diabetes. Am J Med Quality 2003;18:51-8.
8. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41. DOI 10.1345/aph.17095
9. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. Am J Med Quality 2000;15:137-42.
10. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663-9. Erratum 1999;281:1989.
11. Dunn NR, Bough P. Standards of care of diabetic patients in a typical English community. Br J Gen Pract 1996;46:401-5.
12. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
13. Nowak SN, Singh R, Clarke A, Campbell E, Jaber LA. Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic (letter). Diabetes Care 2002;25:1479.
14. Irons BK, Lenz RJ, Anderson SL, Wharton BL, Habeger B, Anderson HG Jr. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-1300.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13.
16. Holman RR. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol 2001;38(suppl 1):S9-14.
17. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.